Plain-English translation of NCT06995651 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a medication called to see how it works in people with cystic fibrosis who have pancreatic insufficiency (when the pancreas doesn't make enough digestive enzymes) and abnormal blood sugar control. The research team wants to understand whether this medication can improve how your body handles blood sugar and insulin after eating. You'll take either the medication or a placebo (a fake pill) for one week, then switch to the other option the following week, so researchers can compare how each affects your body.
People with cystic fibrosis often develop problems controlling their blood sugar because their pancreas doesn't work properly. This medication may help by supporting the pancreas's natural ability to release the right amount of insulin and manage blood sugar more effectively—something that hasn't been well studied in this population before.
You likely qualify if…
You likely don't qualify if…
You will visit the study center for two separate one-week treatment periods. During the first week, you'll take either 50 mg or a placebo pill twice daily by mouth. After a break, you'll return for the second week and take whichever option you didn't receive the first time. During each week, you'll have blood tests and a meal tolerance test (where you eat a standard meal and researchers measure how your body responds). This crossover design lets researchers see how the medication affects your body by comparing your results on both the real medication and placebo.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States